FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, and concerns a dosage form of insulin containing insulin, a dissolving agent, and a zinc chelator, wherein the dosage form has a pH value varying within the range more than pH 7 and pH 7.6, represents a transparent aqueous solution; it also concerns an injection dosage form of insulin; a method of treating a diabetic patient involving the injection of the above dosage form into the patient.
EFFECT: group of inventions provides higher accumulation and transport through the epithelial cells as compared to insulin in a combination of HCl and zinc chelator above.
27 cl, 11 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR AMINO GROUP PEGYLATION TO OBTAIN SITE-SPECIFIC CONJUGATES OF PROTEINS | 2016 |
|
RU2730848C2 |
| NOVEL INSULIN DERIVATIVES AND USE THEREOF | 2015 |
|
RU2684456C2 |
| METHOD FOR DETECTING NEUTRALIZING ANTIBODIES AGAINST RECOMBINANT HUMAN INSULIN IN HUMAN BLOOD SERUM | 2016 |
|
RU2725142C2 |
| NOVEL DERIVATIVE OF INSULIN ANALOGUE | 2014 |
|
RU2673185C2 |
| HALOGEN-STABILISED INSULIN | 2009 |
|
RU2555557C2 |
| COMPLEX CONTAINING HUMAN INSULIN ANALOG AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1995 |
|
RU2152399C2 |
| PHARMACEUTICAL COMPOSITION WITH RAPID ACTING INSULIN | 2010 |
|
RU2500420C2 |
| INSULIN-CONTAINING PROLONGED ACTION PREPARATION | 2015 |
|
RU2676101C2 |
| LONG-ACTING INSULIN COMPOSITION | 2010 |
|
RU2556340C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
